INTRODUCTION Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD)[1]. Pulmonary hypertension (PHT) is a common co-morbidity in patients with CKD and end-stage renal disease (ESRD) [2]. PH is associated with increased risk of hospitalization and mortality in patients with CKD [3].Several ... إقراء المزيد

BACKGROUND The development of pulmonary arterial hypertension (PAH) has been long considered a risk factor for poor outcome in patients undergoing mitral valve replacement (MVR). This prospective study was conducted to assess the operative mortality, immediate postoperative hemodynamics and short term (6 months) survival in patients who underwent MVR in the presence of severe PAH PATIENTS AND METHODS This study ... إقراء المزيد

ABSTRACT: Pulmonary arterial hypertension (PH) is a deadly disease characterized by pulmonary arterial vasoconstriction and hypertension, pulmonary vasculature remodeling, and right ventricular hypertrophy. Our previous in vivo studies, performed in several models of cardiac, vascular, and/or renal injury, suggest that the metabolites of 17beta-estradiol may inhibit vascular and cardiac remodeling. The goal of this study was to determine whether 2-methoxyestradiol ... إقراء المزيد